(Q51129176)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

title

Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

3

Gregory D Ayers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Michael L Schulte

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Matthew R Hight

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Qi Liu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Yu Shyr

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

M Kay Washington

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

H Charles Manning

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

publication date

1 June 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

Molecular Imaging and Biology

26 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

421-428

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11307-016-1008-z

26 March 2020

exact match

0 references

cites work

Targeting cellular metabolism to improve cancer therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Cancer cell metabolism: Warburg and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Glutamine addiction: a new therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Glutamine and cancer: cell biology, physiology, and clinical opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Targeting mitochondrial glutaminase activity inhibits oncogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

[(18)F](2S,4S)-4-(3-Fluoropropyl)glutamine as a tumor imaging agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Rapid, Microwave-Assisted Organic Synthesis of Selective (V600E)BRAF Inhibitors for Preclinical Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Metabolic reprogramming: a cancer hallmark even warburg did not anticipate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Rethinking the Warburg effect with Myc micromanaging glutamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

MYC-induced cancer cell energy metabolism and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-016-1008-Z

Impact of animal handling on the results of 18F-FDG PET studies in mice.

21 January 2018

1 reference

12 December 2020

Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma

1 reference

12 December 2020

Cancer screening with FDG-PET

1 reference

12 December 2020

Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma

1 reference

12 December 2020

10.1007/S11307-016-1008-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27770401%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

PubMed publication ID

27770401

1 reference